Summary
PRA was awarded a rheumatoid arthritis study contract based on our strategy for achieving first-patient-in (FPI) by the end of the calendar year. PRA’s plan depended on a closely managed project with clear timelines and responsibilities, as well as selecting key sites that could support our goal. PRA reduced the project’s cost by approximately 15% through our ability to enroll the targeted number of patients with fewer sites and in a shorter time period.
Register to download
PRA Delivers Study Start-up Success
You may also be interested in:
Blog
Ask the Experts: How Does Immunization Protect Us?
PRA experts from the Center for Vaccine Research—Darin Seehafer, Director of Therapeutic Expertise, and Lynlee Burton, Head, Center for Vaccine…
Case Study
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
Fact Sheet
The Center for Immuno-oncology, Cellular, and Gene Therapy Fact Sheet
The Center for Immuno-oncology, Cellular, and Gene Therapy leverages our comprehensive experience and cross-functional experts to build…